News By Tag * Rheumatoid * Arthritis * 2010-20 * Assumptions * Pipeline * Rheumatoid-arthritis-specific * Tofacitinib * Tanabe * Janssen * John * More Tags... Industry News News By Location Country(s) Industry News
| Just Released: "Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis"New Pharmaceuticals market report from Datamonitor: "Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis - Novel therapies plus reformulations poised to enter the market"
Scope of this report: * Gain insight into the RA competitive landscape and assess commercial opportunity using 10-year patient-based forecasts with clear methodology. * Access current and future patient-numbers and expand knowledge on potential future events that may impact these. * Evaluate existing and potential future brand dynamics by line of therapy; from first- through to fourth-line and beyond. * Enhance understanding of future product potential, with key opinion leader views of late stage kinase inhibitors, such as tofacitinib and FosD. * Gauge the anticipated impact of reformulations on patient switching and the subsequent effect on total brands sales. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Report Highlights: With two novel kinase inhibitors forecast to launch for rheumatoid arthritis and key brand reformulations set to enter the market over the next decade, Datamonitor's patient-based forecast shows that the market will grow to reach $18bn in 2020. Despite news of deaths in a Phase III trial of Pfizer's tofacitinib, physicians remain upbeat on this potential game-changer, stating that while safety is a concern for new drugs, the deaths mirror those seen in the era prior to biologics. Datamonitor forecasts favorable uptake of tofacitinib, reaching sales of $1.2bn by 2020 in the major markets. Opinion leaders verify rising interest to adopt non-TNF biologics earlier in the algorithm, due to familiarity and more experience of their side-effects. With Bristol-Myers Squibb gaining US approval of subcutaneous Orencia (abatacept) in July 2011, this reformulation adds positively to its lifecycle and it will benefit from this projected trend. Reasons to Purchase: * What impact has the deaths in a Phase III trial of tofactinib had on its potential future uptake across the seven major rheumatoid arthritis markets? * What is the future outlook in terms of patients and sales for 2009 market entrants Cimzia and Simponi and how does this compare to older TNF brands? * How will the launch of subcutaneous formulations of marketed intravenous drugs Orencia and Actemra change their usage and impact future brand sales? * How will first-, second-, third- and fourth-line and beyond biologic brand dynamics change in the rheumatoid arthritis markets over the coming decade? * How will each of the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) evolve in terms of patients from 2010 to 2020? Partial Table of Contents: OVERVIEW * Catalyst * Summary EXECUTIVE SUMMARY * Strategic scoping and focus * Datamonitor key findings * Related reports MARKET DEFINITION * Market definition for rheumatoid arthritis * Forecast methodology and assumptions * Methodology flow * Patent expiries * New product launches * Additional forecast methodology SEVEN MAJOR MARKETS OVERVIEW AND CONTEXT * Current and future market dynamics overview * US market bolstered by reformulations and new product launches in the near-term * Launch of additional biologics and uptake of existing brands will grow the Japanese rheumatoid arthritis market * EU austerity measures including price cuts will dampen growth across these rheumatoid arthritis markets * France * Germany * Italy * Spain * UK BRAND FORECASTS * Enbrel rheumatoid arthritis (etanercept; * Forecast assumptions * Enbrel forecast 2010-20 * Humira rheumatoid arthritis (adalimumab; * Forecast assumptions * Humira forecast 2010-20 * Remicade rheumatoid arthritis (infliximab; * Forecast assumptions * Remicade forecast 2010-20 * Simponi rheumatoid arthritis (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) * Forecast assumptions * Simponi forecast 2010-20 * Cimzia rheumatoid arthritis (certolizumab; * Forecast assumptions * Cimzia forecast 2010-20 * Actemra/RoActemra rheumatoid arthritis (tocilizumab; * Forecast assumptions * Actemra/RoActemra forecast 2010-20 * Orencia rheumatoid arthritis (abatacept; Bristol-Myers Squibb) * Forecast assumptions * Orencia forecast 2010-20 * Rituxan/MabThera rheumatoid arthritis (rituximab; /Roche/Chugai/ * Forecast assumptions * Rituxan/MabThera forecast 2010-20 * Tofacitinib rheumatoid arthritis (formerly tasocitinib, CP-690,550; Pfizer) * Forecast assumptions * Tofacitinib forecast 2010-20 * FosD rheumatoid arthritis (fostamatinib disodium; AstraZeneca/ * Forecast assumptions * FosD forecast 2010-20 BIBLIOGRAPHY * Journal papers * Websites * Datamonitor reports APPENDIX * Contributing experts * Forecast methodology * Volume and value forecast methodology * Price and compliance assumptions * Physician sample breakdown * Primary research questions * Report methodology TABLES * Table: Summary of therapeutic classes in rheumatoid arthritis, by ATC code, 2011 * Table: Patent expiry dates for key marketed brands in rheumatoid arthritis across the seven major markets, out to 2020 * Table: Estimated launch dates for key late-stage pipeline products and marketed brands in rheumatoid arthritis in the seven major markets, 2010-20 * Table: Rheumatoid arthritis market sales across the seven major markets, by class ($m), 2010-20 * Table: Enbrel (etanercept; * Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number